NCT04458688View on ClinicalTrials.gov

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

November 20, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2030

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
OTHER

Observation of Ocrelizumab as Treatment in RRMS Patients

It is decided by the patient and their physician to begin taking ocrelizumab PRIOR to study enrollment. The study is only observing the effects of ocrelizumab as a pre-decided treatment option for a patient's MS.

Trial Locations (1)

48201

RECRUITING

Wayne State University, Detroit

All Listed Sponsors
lead

Wayne State University

OTHER